Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2005
12/01/2005US20050267040 Hepatitis C virus inhibitors
12/01/2005US20050267038 Novel diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use
12/01/2005US20050267037 Methods and compositions for treating cancer using proteasome inhibitors
12/01/2005US20050267032 Sulfone-containing prodrugs
12/01/2005US20050267023 Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
12/01/2005US20050267022 Identification of novel factors that block programmed cell death or apoptosis by targeting JNK
12/01/2005US20050267018 Macrocyclic compounds as inhibitors of viral replication
12/01/2005US20050267016 Therapeutic oligopeptide for treatment of tumor disorders; contacting the tumor with a therapeutically effective amount of a CD10 cleavable prodrug, wherein tumor is comprised of one or more target cells which express CD10 for at least a portion of the target cell life cycle
12/01/2005US20050267014 Pharmaceutical composition comprising factor VII polypeptides and tranexamic acid
12/01/2005US20050267013 Methods for affecting various diseases utilizing LXR compounds
12/01/2005US20050267012 Contacting with Bacillus anthracis lethal factor
12/01/2005US20050266515 Glyceraldehyde 3-phosphate dehydrogenase-S (GAPDHS), a glycolytic anzyme expressed only in male germ cells, is a target for male contraception
12/01/2005US20050266486 Methods for treating obesity by inhibiting expression of obese gene product receptor variant
12/01/2005US20050266457 Modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms
12/01/2005US20050266107 Administering mixture of flavopereirine and alstonine for preventing prostate cancer and/or reducing PSA levels and/or alleviating the symptoms of BPH (Benign Prostatic Hyperplasia) or PIN (prostatic intraepithelial neoplasia)
12/01/2005US20050266104 Efficient method for producing compositions enriched in total phenols
12/01/2005US20050266098 Composition for treatment of a hydrofluoric acid burn
12/01/2005US20050266096 New synergetic compositions of vitamins, minerals and trace-elements to stimulate the elimination of intra-cellular lipid deposits
12/01/2005US20050266092 Loaded microspheres
12/01/2005US20050266089 Contact lens and eye drop rewetter compositions and methods
12/01/2005US20050266088 Formulation for fast dissolution of lipophilic compounds
12/01/2005US20050266087 Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
12/01/2005US20050266086 Intrauterine applications of materials formed in situ
12/01/2005US20050266084 Modified release dosage forms
12/01/2005US20050266083 Vehicles for delivery of biologically active substances
12/01/2005US20050266082 Preparation of stable paroxetine HC1 ER tablets using a melt granulation process
12/01/2005US20050266080 Coated tablet formulation and method
12/01/2005US20050266079 Process for making aqueous coated beadlets
12/01/2005US20050266078 Compressed tablets comprising microcapsules with modified release
12/01/2005US20050266076 Resorbable delivery systems for the treatment of cancer
12/01/2005US20050266075 Omeprazole dosage form
12/01/2005US20050266073 Fast disintegrating granules containing bromhexin/bromhexinhydrochloride, process for their preparation, and their use in veterinary medicine
12/01/2005US20050266072 Pharmaceutical compositions
12/01/2005US20050266071 Acid labile proton pump inhibitor microencapsulated with material that enhances shelf-life of pharmaceutical formulation, and antacid, wherein initial serum concentration of proton pump inhibitor is greater than 0.1 mu g/ml at any time within 30 minutes after administration of pharmaceutical; shelf life
12/01/2005US20050266068 Cardiolipin molecules and methods of synthesis
12/01/2005US20050266067 Nanocell drug delivery system
12/01/2005US20050266064 Cosmetic compositions and methods
12/01/2005US20050266062 Percutaneous absorption preparation containing 3-methyl-1-phenyl-2-pyrazolin-5-one
12/01/2005US20050266061 Transdermal delivery of cannabinoids
12/01/2005US20050266060 Transdermal delivery system for treatment of cognitive disorders
12/01/2005US20050266058 Topical preparations containing ambroxol
12/01/2005US20050266051 Pet food compositions and methods
12/01/2005US20050266047 Injectable glaucoma implants with multiple openings
12/01/2005US20050266040 Medical devices composed of porous metallic materials for delivering biologically active materials
12/01/2005US20050266039 Coated medical device and method for making the same
12/01/2005US20050266035 Skin protectant spray compositions
12/01/2005US20050266032 Dosage form containing multiple drugs
12/01/2005US20050266028 Compositions and methods for modulating an immune response
12/01/2005US20050266024 Adjuvant
12/01/2005US20050266012 Compositions comprising demethylating agents as enhancers of immunotherapy for the treatment of chronic infections and neoplastic diseases and methods for treating the same
12/01/2005US20050265999 Modulation of 5-HT2 receptors as a treatment for cardiovascular diseases
12/01/2005US20050265991 For controlled release of compounds through the use of a chemically sensitive cantilever
12/01/2005US20050265990 Treatments and nutritional supplements for assisting post-exercise recovery
12/01/2005US20050265970 Identifying agents which modify mitogen activated kinase activities associated with cell death; small interfering RNA and treament of cell proliferative disorders; for modulating diseases and conditions associated with elevated or decreased apoptosis
12/01/2005US20050265965 Modified cytokines for use in cancer therapy
12/01/2005US20050265959 Hydroxyphenyl cross-linked macromolecular network and applications thereof
12/01/2005US20050265958 Nitric oxide releasing compositions and associated methods
12/01/2005US20050265955 Sustained release preparations
12/01/2005US20050265954 Novel association, a method of its preparation and its uses
12/01/2005US20050265944 Carbohydrate-based anti-wrinkle and tissue remodelling compounds
12/01/2005US20050265930 Consisting of 20 to 55 wt. % of a cyclohexane carboxamide selected from N-ethyl-3-p-menthane carboxamide, N-(ethoxycarbonylmethyl)-3-p-menthane carboxamide, and mixtures thereof, 15 to 45 wt. % of N,2,3-trimethyl-2-isopropyl butanamide, and 20 to 55 wt. % menthyl lactate; use in foods, drugs, cosmetics
12/01/2005US20050265927 Intranasal delivery of nucleic acid molecules
12/01/2005DE19710916B4 Ascorbinsäure als Adjuvans bei der Beseitigung von Gefäßverschlüssen Ascorbic acid as an adjuvant in removing vascular occlusions
12/01/2005DE10342095B4 Verwendung einer Applikationsanordnung für auf die Haut aufzutragende, tinkturartige Heilmittel Using a delivery arrangement for be applied to the skin, tinkturartige remedies
12/01/2005DE102004023522A1 Substituierte Cyclohexyl-1,4-diamin-Derivate Substituted cyclohexyl-1,4-diamine derivatives
12/01/2005DE102004022970A1 Neue Imidazolderivate, deren Herstellung und deren Verwendung als Intermediate zur Herstellung von Arzneimitteln und Pestiziden New Imidazole derivatives, their preparation and their use as intermediates for the preparation of medicaments and pesticides,
12/01/2005DE102004022392A1 Desinfektionsmittel-Zusammensetzung enthaltend zumindest eine Persäure-Verbindung und deren Verwendung zur Raum- und Luftdesinfektion Disinfectant composition containing at least a peracid compound and their use for the spatial and air disinfection
12/01/2005DE102004022383A1 New pyridopyrazine derivatives are modulators of kinase activity, useful for the treatment of diseases associated with abnormal cellular signaling, e.g. tumors
12/01/2005DE102004021658A1 Anticancer product comprises 2-methylthiazolidine-2,4-dicarboxylic acid and an antiangiogenic, cytotoxic or cytostatic compound
12/01/2005DE102004021637A1 Dihydrobenzothiophene Dihydrobenzothiophene
12/01/2005CA2838526A1 Intravitreal implants comprising microspheres which encapsulate a tyrosine kinase inhibitor and a biodegradable polymer
12/01/2005CA2826538A1 3-triazolyl-galactoside inhibitors of galectins
12/01/2005CA2824701A1 Modulation of glucose-6-phosphate translocase expression
12/01/2005CA2776682A1 Tiacumicin b compound
12/01/2005CA2767912A1 Synthesis of tetracyclines and analogues thereof
12/01/2005CA2730540A1 Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
12/01/2005CA2578549A1 Flavopereirine and alstonine combinations in the treatment and prevention of prostate cancer
12/01/2005CA2572446A1 Combinatorial selection of phosphorothioate aptamers for tgf-beta
12/01/2005CA2567854A1 Dpp-iv inhibitors
12/01/2005CA2567704A1 Selective serotonin receptor inverse agonists as therapeutics for disease
12/01/2005CA2567700A1 3-triazolyl-galactoside inhibitors of galectins
12/01/2005CA2567694A1 Novel galactoside inhibitors of galectins
12/01/2005CA2567506A1 Cyclic amide derivatives, and their production and use as antithrombotic agents
12/01/2005CA2567483A1 Pyrazinylmethyl lactam derivatives
12/01/2005CA2567404A1 Cyclopenta[b]benzofuran derivatives and the utilization thereof
12/01/2005CA2567352A1 5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes
12/01/2005CA2567343A1 N-cyclic sulfonamido inhibitors of gamma secretase
12/01/2005CA2567329A1 Rapid setting calcium phosphate cements
12/01/2005CA2567298A1 Methods and related compositions for reduction of fat
12/01/2005CA2567228A1 Thiophene heteroaryl amines
12/01/2005CA2567190A1 Combinations of hyaluronic acid and polyunsaturated fatty acids
12/01/2005CA2567189A1 Treatment for asthma and arthritis and other inflammatory diseases
12/01/2005CA2566937A1 Substituted 2,5-diaminomethyl-1h-pyrroles
12/01/2005CA2566934A1 Tetrahydronaphthyl- piperazines as 5-ht1b antagonists, inverse agonists and partial agonists
12/01/2005CA2566923A1 2-((hetero) aryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
12/01/2005CA2566920A1 Metabolites of (+)-(2s, 3s)-3-(2-methoxy-5-trifluoromethoxybenzylamino)-2-phenyl-piperidine
12/01/2005CA2566892A1 Substituted 5-aminomethyl-1h-pyrrol-2-carbxylic acid amides
12/01/2005CA2566873A1 Use of drug combinations for treating insulin resistance
12/01/2005CA2566850A1 Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a gst-activated anticancer compound
12/01/2005CA2566755A1 Hiv integrase inhibitors: cyclic pyrimidinone compounds
1 ... 4450 4451 4452 4453 4454 4455 4456 4457 4458 4459 4460 4461 4462 4463 4464 4465 4466 4467 4468 4469 4470 ... 7860